Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
20.35 -0.07 (-0.34%) 03/17/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 20.35 unch (unch) 16:40 ET
Quote Overview for Mon, Mar 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
19.70
Day High
21.00
Open 20.42
Previous Close 20.42 20.42
Volume 734,200 734,200
Avg Vol 741,160 741,160
Stochastic %K 44.69% 44.69%
Weighted Alpha -52.74 -52.74
5-Day Change +0.79 (+4.04%) +0.79 (+4.04%)
52-Week Range 18.61 - 47.00 18.61 - 47.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,355,561
  • Shares Outstanding, K 66,384
  • Annual Sales, $ 7,020 K
  • Annual Income, $ -157,860 K
  • EBIT $ -195 M
  • EBITDA $ -208 M
  • 60-Month Beta 1.76
  • Price/Sales 190.45
  • Price/Cash Flow N/A
  • Price/Book 1.79

Options Overview Details

View History
  • Implied Volatility 93.62% ( -9.99%)
  • Historical Volatility 50.45%
  • IV Percentile 94%
  • IV Rank 69.94%
  • IV High 116.13% on 09/17/24
  • IV Low 41.26% on 06/24/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 24
  • Volume Avg (30-Day) 93
  • Put/Call OI Ratio 1.32
  • Today's Open Interest 6,490
  • Open Int (30-Day) 6,952

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 5
  • High Estimate -0.65
  • Low Estimate -0.88
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -33.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.61 +9.35%
on 03/04/25
Period Open: 22.70
23.37 -12.92%
on 02/21/25
-2.35 (-10.35%)
since 02/14/25
3-Month
18.61 +9.35%
on 03/04/25
Period Open: 26.04
29.05 -29.95%
on 01/08/25
-5.69 (-21.85%)
since 12/17/24
52-Week
18.61 +9.35%
on 03/04/25
Period Open: 42.01
47.00 -56.70%
on 09/25/24
-21.66 (-51.56%)
since 03/15/24

Most Recent Stories

More News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 31.99 (+3.43%)
CLDX : 20.35 (-0.34%)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeutics  (NASDAQ:...

AGIO : 31.99 (+3.43%)
CLDX : 20.35 (-0.34%)
Celldex Therapeutics to Present at Upcoming Investor Conferences

CLDX : 20.35 (-0.34%)
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

CLDX : 20.35 (-0.34%)
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

CLDX : 20.35 (-0.34%)
Celldex: Q4 Earnings Snapshot

Celldex: Q4 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

CLDX : 20.35 (-0.34%)
Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment

Celldex Therapeutics initiates Phase 2 study of barzolvolimab for treating atopic dermatitis, currently enrolling patients.Quiver AI SummaryCelldex Therapeutics has launched a Phase 2 study of its monoclonal...

CLDX : 20.35 (-0.34%)
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

CLDX : 20.35 (-0.34%)
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation

Celldex Therapeutics began Phase 1a study of CDX-622, targeting chronic inflammation through a bispecific antibody approach.Quiver AI SummaryCelldex Therapeutics, Inc. has announced the commencement of...

CLDX : 20.35 (-0.34%)
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

CLDX : 20.35 (-0.34%)
Celldex Therapeutics to Present at Upcoming Investor Conferences

CLDX : 20.35 (-0.34%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

CLDX : 20.35 (-0.34%)
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

CLDX : 20.35 (-0.34%)
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

CLDX : 20.35 (-0.34%)
Can This Growth Stock Deliver 135% Upside in 2025?

Positive clinical trial results have sparked hope for this biotech.

CLDX : 20.35 (-0.34%)
$SPX : 5,675.12 (+0.64%)
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for...

CLDX : 20.35 (-0.34%)
KRYS : 186.89 (+4.19%)
FULC : 3.12 (unch)
ANIP : 64.35 (+2.98%)
Celldex: Q2 Earnings Snapshot

Celldex: Q2 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Stocks Post Modest Gains on Mixed US Economic Reports

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.03%. Stock indexes today are slightly...

$SPX : 5,675.12 (+0.64%)
SPY : 567.15 (+0.77%)
$DOWI : 41,841.63 (+0.85%)
DIA : 419.21 (+0.93%)
$IUXX : 19,812.24 (+0.55%)
QQQ : 482.77 (+0.65%)
ZNM25 : 110-205 (+0.03%)
MU : 103.11 (+2.30%)
QCOM : 157.95 (+0.87%)
LZB : 38.42 (+0.13%)
CLDX : 20.35 (-0.34%)
KR : 66.39 (+1.98%)
Celldex: Q1 Earnings Snapshot

Celldex: Q1 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex: Q4 Earnings Snapshot

Celldex: Q4 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Why Celldex Therapeutics Blasted 13% Higher on Monday

The biotech's CSU treatment advanced in the laboratory.

CLDX : 20.35 (-0.34%)
Freshpet, Celldex Therapeutics rise; TreeHouse Foods, Dish Network fall, Monday, 11/6/2023

Stocks that traded heavily or had substantial price changes on Monday: Freshpet, Celldex Therapeutics rise; TreeHouse Foods, Dish Network fall

CLDX : 20.35 (-0.34%)
THS : 27.98 (-0.50%)
HGV : 36.80 (+5.38%)
DISH : 5.77 (+1.94%)
FRPT : 89.32 (+1.68%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex: Q2 Earnings Snapshot

Celldex: Q2 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex: Q1 Earnings Snapshot

Celldex: Q1 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex: Q4 Earnings Snapshot

Celldex: Q4 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 20.35 (-0.34%)
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2...

CLDX : 20.35 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 22.30
2nd Resistance Point 21.65
1st Resistance Point 21.00
Last Price 20.35
1st Support Level 19.70
2nd Support Level 19.05
3rd Support Level 18.40

See More

52-Week High 47.00
Fibonacci 61.8% 36.16
Fibonacci 50% 32.81
Fibonacci 38.2% 29.45
Last Price 20.35
52-Week Low 18.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals